RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers - Seite 2
“These biomarker data provide further evidence that FLX475 reduces Treg in the tumor and promotes a permissive environment that should enhance immune-based therapy including checkpoint inhibitors,” said Dirk Brockstedt, Ph.D., chief scientific officer of RAPT. “In addition to inhibiting the recruitment of regulatory T cells, which are highly potent suppressors of an antitumor immune response, we saw a concomitant increase in cancer fighting effector T cells and additional beneficial changes in the tumor microenvironment that have been shown to correlate with a favorable response to anti-PD(L)1 therapy. These data are consistent with and support the clinical activity we’ve seen with FLX475 as monotherapy and in combination therapy with pembrolizumab.”
About FLX475
FLX475 is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues. Treg represent
a dominant pathway for downregulating the immune response, generally correlate with poor clinical outcomes, and may limit the effectiveness of currently available therapies such as checkpoint
inhibitors. FLX475 may restore naturally occurring antitumor immunity alone and may synergize with a variety of both conventional and immune-based therapies, such as radiation, chemotherapy,
checkpoint inhibitors, immune stimulators, cancer vaccines, and adoptive T cell therapy.
Lesen Sie auch
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet
needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical
immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of
inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.